Balzano Elisa, Di Tommaso Elena, Antoccia Antonio, Pelliccia Franca, Giunta Simona
Laboratory of Molecular Cytogenetics, Dipartimento di Biologia e Biotecnologie "Charles Darwin", Sapienza Università di Roma, Roma, Italy.
Laboratory of Genome Evolution, Dipartimento di Biologia e Biotecnologie "Charles Darwin", Sapienza Università di Roma, Roma, Italy.
Front Genet. 2022 Jan 28;12:810793. doi: 10.3389/fgene.2021.810793. eCollection 2021.
Glioblastoma multiforme (GBM) is a malignant tumor of the central nervous system (CNS). The poor prognosis of GBM due to resistance to therapy has been associated with high chromosomal instability (CIN). Replication stress is a major cause of CIN that manifests as chromosome rearrangements, fragility, and breaks, including those cytologically expressed within specific chromosome regions named common fragile sites (CFSs). In this work, we characterized the expression of human CFSs in the glioblastoma U-251 MG cell line upon treatment with the inhibitor of DNA polymerase alpha aphidicolin (APH). We observed 52 gaps/breaks located within previously characterized CFSs. We found 17 to be CFSs in GBM cells upon treatment with APH, showing a frequency equal to at least 1% of the total gaps/breaks. We report that two CFSs localized to regions FRA2E (2p13/p12) and FRA2F (2q22) were only found in U-251 MG cells, but not lymphocytes or fibroblasts, after APH treatment. Notably, these glioblastoma-specific CFSs had a relatively high expression compared to the other CFSs with breakage frequency between ∼7 and 9%. Presence of long genes, incomplete replication, and delayed DNA synthesis during mitosis (MiDAS) after APH treatment suggest that an impaired replication process may contribute to this loci-specific fragility in U-251 MG cells. Altogether, our work offers a characterization of common fragile site expression in glioblastoma U-251 MG cells that may be further exploited for cytogenetic and clinical studies to advance our understanding of this incurable cancer.
多形性胶质母细胞瘤(GBM)是中枢神经系统(CNS)的一种恶性肿瘤。由于对治疗产生耐药性,GBM的预后较差,这与高染色体不稳定性(CIN)有关。复制应激是CIN的主要原因,表现为染色体重排、脆性和断裂,包括在特定染色体区域(称为常见脆性位点,CFSs)内细胞学上表达的那些。在这项工作中,我们对胶质母细胞瘤U - 251 MG细胞系在用DNA聚合酶α抑制剂阿非科林(APH)处理后人类CFSs的表达进行了表征。我们观察到52个缺口/断裂位于先前表征的CFSs内。我们发现用APH处理后,GBM细胞中有17个是CFSs,其频率至少占总缺口/断裂的1%。我们报告说,在用APH处理后,仅在U - 251 MG细胞中发现了定位于FRA2E(2p13/p12)和FRA2F(2q22)区域的两个CFSs,而在淋巴细胞或成纤维细胞中未发现。值得注意的是,与其他断裂频率在7%至9%之间的CFSs相比,这些胶质母细胞瘤特异性CFSs具有相对较高的表达。APH处理后长基因的存在、不完全复制以及有丝分裂期间的延迟DNA合成(MiDAS)表明,复制过程受损可能导致U - 251 MG细胞中这种位点特异性脆性。总之,我们的工作对胶质母细胞瘤U - 251 MG细胞中常见脆性位点的表达进行了表征,这可能会在细胞遗传学和临床研究中得到进一步利用,以加深我们对这种无法治愈的癌症的理解。